Y-Intercept (HK)’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Y-Intercept (HK)’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,889	Closed	-$1.48M	–	1829
2025 Q4	$1.48M	Buy	35,889 +29,494	+461%	+$1.18M	0.03%	777
2025 Q3	$248K	Sell	6,395 -53,169	-89%	-$1.73M	0.01%	1429
2025 Q2	$1.65M	Buy	+59,564	New	+$1.52M	0.04%	691
2025 Q1	–	Sell	-13,050	Closed	-$258K	–	1421
2024 Q4	$258K	Buy	+13,050	New	+$298K	0.02%	977
2024 Q3	–	Sell	-29,093	Closed	-$543K	–	1568
2024 Q2	$543K	Buy	+29,093	New	+$545K	0.03%	773
2024 Q1	–	Sell	-12,180	Closed	-$214K	–	1579
2023 Q4	$214K	Buy	+12,180	New	+$200K	0.02%	981
2023 Q1	–	Sell	-12,920	Closed	-$194K	–	1356
2022 Q4	$194K	Buy	+12,920	New	+$188K	0.03%	839

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Y-Intercept (HK)'s KNSA Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 35,889 shares — an estimated $1.48M sold.

Y-Intercept (HK) first reported a position in KNSA in Q4 2022 and held it in 7 quarters. The position peaked at $1.65M in Q2 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Y-Intercept (HK) reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 35,889 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $1.48M.
Y-Intercept (HK) first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and held it in 7 quarters.
Y-Intercept (HK)'s Kiniksa Pharmaceuticals position peaked at $1.65M in Q2 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.